Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Fosun to Pay up to $148 Million for China Rights to MimiVax Glioblastoma Treatment

publication date: Nov 18, 2019

Shanghai Fosun Pharma announced a $148 million agreement to acquire China rights to SurVaxM, a novel immunotherapy aimed at glioblastoma, from MimiVax of Buffalo, New York. SurVaxM, a novel peptide mimic vaccine, stimulates the immune system to kill tumor cells that contain survivin, a protein that helps cancer cells resist conventional treatments. In a US Phase II trial among glioblastoma patients, SurVaxM showed improved efficacy combined with an acceptable safety profile. MimiVax, which notes that survivin is present in many cancers, is also conducting a multiple myeloma trial. More details....

Stock Symbols; (SHA: 600196; HK: 2196)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.